The posttranslational addition of a farnesyl moiety to the Ras oncoprotein is essential for its transforming activity. Cell-active inhibitors of the enzyme that catalyzes this reaction, protein farnesyltransferase, have been shown to selectively block ras-dependent transformation of cells in culture. Here we describe the protein farnesyltransferase inhibitor 
The protein product of the ras gene, Ras, functions in the regulation of cell proliferation (1) . As for other lowmolecular-weight GTP-binding proteins, Ras (1, 2) .
Ras is synthesized as a cytosolic precursor that localizes to the plasma membrane after a series of posttranslational modifications (3, 4) . The first reaction in this series involves the addition of a farnesyl group to the cysteine residue of the C-terminal CAAX sequence (where C is cysteine, A is an aliphatic residue, and X represents any residue) in a reaction catalyzed by the enzyme protein farnesyltransferase (PFTase) . Subsequently, the AAX residues are proteolytically cleaved, and the now C-terminal farnesylcysteine is methylated. Only the farnesylation reaction is essential for the transforming activity of the Ras oncoprotein (5) (6) (7) (8) . Thus, inhibitors of PFTase have been proposed as potential inhibitors of ras-dependent transformation that may be useful in the treatment of those cancers where Ras plays a role.
Synthetic PFTase inhibitors have been designed based on the two substrates of the reaction, farnesyl diphosphate and the Ras CAAX tetrapeptide, that portion of the Ras protein that is sufficient for interaction with the enzyme (9, 10) . Recently, CAAX analogs have been synthesized that are potent inhibitors of PFTase (11) (12) (13) (14) . Several of these compounds have been shown to modulate critical aspects of Ras transformation in whole cells, including inhibition of anchorage-dependent (12) and anchorage-independent growth (13), morphological reversion (12) , and inhibition of oocyte maturation induced by oncogenic Ras (11 100 ,uM] and selectively blocked the anchorage-independent growth of ras-transformed cells (at 1 mM). The modest potency of this compound in cell culture is due, in part, to chemical instability: at neutral pH, rapid cyclization of the lactone carbonyl group to the proximal amino group of the backbone of L-731,734 occurs to form a diketopiperazine, which is =300-fold less potent as an inhibitor of PFTase (S.D.M., S.J.d., J.B.G., and S.L.G., unpublished data). The current compounds were designed to eliminate this mode of reactivity by replacing the nucleophilic nitrogen with an ether oxygen. Structural modification in this series of compounds led to 2(S)-{2(S)-[2(R)-amino-3-mercapto]propylamino-3(S)-methyl}pentyloxy-3-phenylpropionylmethionine sulfone (L-739,750) and its methyl ester L-739,749 (Fig. 1) . The stability of the esters in this series of compounds was enhanced >10-fold relative to (12, 13) .
L-739,749 was a potent and selective inhibitor of the anchorage-independent growth of ras-transformed cells. In the presence of diluent alone, the Ratl/Ras cells formed multiple, large colonies (Fig. 2) . Complete inhibition of the growth of the Ratl/Ras cells was observed at 10 ,uM L-739,749, and partial inhibition was achieved with concentrations of L-739,749 as low as 2.5 uM (Fig. 2) . L-739,749 similarly inhibited the anchorage-independent growth ofRatl cells transformed by oncogenically mutated human H-, K-, and N-ras genes (data not shown). To evaluate the specificity of L-739,749 for Ras-induced cell transformation, Ratl cells transformed with either the v-raf or v-mos oncogenes were included in the analysis. Neither Raf nor Mos requires farnesylation to achieve biological activity, and both proteins appear to transform cells independently of . No effect was observed on the anchorage-independent growth of the Ratl/Raf (Fig. 2) L-739,749 also inhibited the anchorage-independent growth of the human pancreatic adenocarcinoma cell line genically mutated human H-, K-, or N-ras genes were injected s.c. into nude mice. To evaluate the specificity of L-739,749 for inhibition of ras-dependent tumor growth, additional mice were injected with Ratl/Raf or Ratl/Mos cells. Two days later, the mice within each of the five oncogene groups were randomly assigned to either the control or L-739,749 treatment groups. PBS or L-739,749 at 20 mg/kg was administered i.p. once daily for 5 days. When all the PBS-treated animals exhibited lesions of 0.5-1.5 cm in diameter, the tumors were excised and weighed; for most animals, this occurred 5 days after the last treatment. In the case of mice bearing raf tumors, tumor excision occurred 9 days after the last treatment. As shown in Table 2 , there was a significant decrease in the average weight of all the rasdependent tumors from mice treated with L-739,749 relative to those treated with PBS. The percentage decrease ranged from 51% for the N-ras-dependent tumors to 66% for the H-ras-dependent tumors. In contrast, there was no significant difference in the average weights between the PBS-and L-739,749-treated raf-and mos-dependent tumors. The inhibition of tumor growth by L-739,749 was dose-dependent. A 10-fold dilution of the compound did not significantly decrease the weights of the H-ras-dependent tumors relative to controls.
Having found that L-739,749 would inhibit ras-dependent tumor growth by 51-66% in nude mice, it was important to determine the extent of tumor inhibition that a standard chemotherapeutic agent would produce in the same model system. In parallel studies, Ratl/huH-Ras cells were again injected into nude mice on day 0, and the animals were treated with doxorubicin at 2 mg/kg per day for 5 days beginning on day 2. Doxorubicin produced a 33% reduction in the weight of the Ratl/huH-Ras tumors relative to controls treated with PBS. It should be emphasized that doxorubicin was used at its maximally tolerated dose in these studies. All of the doxorubicin-treated animals exhibited signs of systemic toxicity-including weight loss, anorexia, and inactivity during the week after their doxorubicin therapy. (28) , have been shown to block tumor growth. Lovastatin, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (29) , blocks the synthesis of isoprenyl pyrophosphates, as well as cholesterol. The mechanism by which limonene, the major monoterpene in orange peel oil, inhibits cellular isoprenylation is unclear. Manumycin is capable of inhibiting PFTase in vitro and has been reported to inhibit the growth of a ras-dependent tumor in nude mice (30) . However, the mechanism by which this antibiotic produces its inhibitory effect in vivo is unclear because PFTase inhibition was not evaluated in cultured cells.
It is likely that the antitumor effects of L-739,749 are due to its inhibition of PFTase activity. L-739,750, the acid of L-739,749, is a potent and specific inhibitor of PFTase in vitro (Table 1) . L-739,749 also exhibits selectivity in cell culture where processing of Ras proteins is blocked, but proteins engineered to be substrates for PGGTase-I are unaffected (ref. 13 (11) . These studies suggest that the antitumor effects of L-739,749 are due to its inhibition of PFTase activity. The ability of L-739,749 to block the anchorage-independent growth of ras-transformed cell lines in soft agar is consistent with previous observations showing that genetic disruptions of a mutant K-ras gene in two human colon cancer cell lines also resulted in their loss of anchorage-independent growth (31) .
The current studies suggest that PFTase inhibitors such as L-739,749 will not only be effective antitumor drugs but may also prove to be remarkably safe chemotherapeutic agents. No evidence of gross toxicity or microscopic histological abnormalities was noted at autopsy in any of the L-739,749-treated mice. The ability of PFTase inhibitors to selectively target the fundamental mechanism responsible for oncogenesis in ras-transformed cells (i.e., ras-mediated signaltransduction events) rather than to interfere with the secondary biological properties common to all transformed cells (e.g., increased DNA and protein synthesis) may account for the remarkable therapeutic ratio (efficacy versus toxicity) exhibited by L-739,749 in animals.
The therapeutic ratio achieved with L-739,749 is somewhat surprising, given that farnesylation is necessary for the biological activity of a number of essential cellular proteins, such as the nuclear lamins (32) . While the reasons for the lack of systemic cytotoxicity of L-739,749 are not known, several points deserve consideration (see also ref. 33 ). First, farnesylated proteins may display differential sensitivity to the inhibitor. In this regard, it has been shown that higher concentrations of CAAX-based PFTase inhibitors are required to inhibit farnesylation of the nuclear lamins than are required to inhibit Ras processing (11, 12) . Additionally, among the farnesylated proteins, there may be variability in the minimum amount of functional (farnesylated) protein required for cellular proliferation. Finally, the lack of absolute specificity of the prenyltransferases has been demonstrated in vitro with mammalian enzymes (19) and in the yeast Saccharomyces cerevisiae (34, 35) . Thus, the possibility exists that, in mammalian cells lacking PFTase activity, PGGTase type I may prenylate some proteins that would otherwise be farnesylated, thus restoring function.
